225 Fatty Acid Oxidation in PLN R14del Cardiomyopathy 8 3. Zwaag PA van der, Rijsingen IAW van, Asimaki A, Jongbloed JDH, Veldhuisen DJ van, Wiesfeld ACP, Cox MGPJ, Lochem LT van, Boer RA de, Hofstra RMW, Christiaans I, Spaendonck-Zwarts KY van, Lekanne dit Deprez RH, Judge DP, Calkins H, Suurmeijer AJH, Hauer RNW, Saffitz JE, Wilde AAM, Berg MP van den, Tintelen JP van. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail 2012;14:1199–1207. 4. Hof IE, Heijden JF van der, Kranias EG, Sanoudou D, Boer RA de, Tintelen JP van, Zwaag PA van der, Doevendans PA. Prevalence and cardiac phenotype of patients with a phospholamban mutation. Neth Heart J 2019;27:64– 69. 5. Doevendans PA, Glijnis PC, Kranias EG. Leducq Transatlantic Network of Excellence to Cure PhospholambanInduced Cardiomyopathy (CURE-PLaN). Circ Res 2019;125:720–724. 6. Karakikes I, Stillitano F, Nonnenmacher M, Tzimas C, Sanoudou D, Termglinchan V, Kong C-W, Rushing S, Hansen J, Ceholski D, Kolokathis F, Kremastinos D, Katoulis A, Ren L, Cohen N, Gho JMIH, Tsiapras D, Vink A, Wu JC, Asselbergs FW, Li RA, Hulot J-S, Kranias EG, Hajjar RJ. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun 2015;6:6955. 7. Cuello F, Knaust AE, Saleem U, Loos M, Raabe J, Mosqueira D, Laufer S, Schweizer M, Kraak P van der, Flenner F, Ulmer BM, Braren I, Yin X, Theofilatos K, Ruiz-Orera J, Patone G, Klampe B, Schulze T, Piasecki A, Pinto Y, Vink A, Hübner N, Harding S, Mayr M, Denning C, Eschenhagen T, Hansen A. Impairment of the ER/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation. EMBO Mol Med 2021;13:e13074. 8. Te Rijdt WP, Tintelen JP van, Vink A, Wal AC van der, Boer RA de, Berg MP van den, Suurmeijer AJH. Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology 2016;69:542–550. 9. Gho JMIH, Es R van, Stathonikos N, Harakalova M, Rijdt WP te, Suurmeijer AJH, Heijden JF van der, Jonge N de, Chamuleau SAJ, Weger RA de, Asselbergs FW, Vink A. High resolution systematic digital histological quantification of cardiac fibrosis and adipose tissue in phospholamban p.Arg14del mutation associated cardiomyopathy. PLoS One 2014;9:e94820. 10. Te Rijdt WP, Asimaki A, Jongbloed JDH, Hoorntje ET, Lazzarini E, Zwaag PA van der, Boer RA de, Tintelen JP van, Saffitz JE, Berg MP van den, Suurmeijer AJH. Distinct molecular signature of phospholamban p.Arg14del arrhythmogenic cardiomyopathy. Cardiovasc Pathol 2019;40:2–6. 11. Sepehrkhouy S, Gho JMIH, Es R van, Harakalova M, Jonge N de, Dooijes D, Smagt JJ van der, Buijsrogge MP, Hauer RNW, Goldschmeding R, Weger RA de, Asselbergs FW, Vink A. Distinct fibrosis pattern in desmosomal and phospholamban mutation carriers in hereditary cardiomyopathies. Heart Rhythm 2017;14:1024–1032. 12. Justus M. B. Anumonwo TH. Fatty Infiltration of the Myocardium and Arrhythmogenesis: Potential Cellular and Molecular Mechanisms. Front Physiol 2018;9. 13. Te Rijdt WP, Ten Sande JN, Gorter TM, Zwaag PA van der, Rijsingen IA van, Boekholdt SM, Tintelen JP van, Haelst PL van, Planken RN, Boer RA de, Suurmeijer AJH, Veldhuisen DJ van, Wilde AAM, Willems TP, Dessel PFHM van, Berg MP van den. Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. Eur Heart J Cardiovasc Imaging 2019;20:92–100. 14. Kamel SM, Opbergen CJM van, Koopman CD, Verkerk AO, Boukens BJD, Jonge B de, Onderwater YL, Alebeek E van, Chocron S, Polidoro Pontalti C, Weuring WJ, Vos MA, Boer TP de, Veen TAB van, Bakkers J. Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy. Nat Commun 2021;12. 15. Eijgenraam TR, Boukens BJ, Boogerd CJ, Marloes Schouten E, Kolk CWA van de, Stege NM, Rijdt WP te, Hoorntje ET, Zwaag PA van der, Rooij E van, Tintelen JP van, Berg MP van den, Meer P van der, Velden J van der, Silljé HHW, Boer RA de. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy. Sci Rep 2020;10:1–13. 16. Raad N, Bittihn P, Cacheux M, Jeong D, Ilkan Z, Ceholski D, Kohlbrenner E, Zhang L, Cai CL, Kranias EG, Hajjar RJ, Stillitano F, Akar FG. Arrhythmia Mechanism and Dynamics in a Humanized Mouse Model of Inherited Cardiomyopathy Caused by Phospholamban R14del Mutation. Circulation 2021;144.
RkJQdWJsaXNoZXIy MTk4NDMw